The Global Hormonal Contraceptives Market is valued at USD 16.36 Billion in 2022 and is expected to reach USD 28.81 Billion by 2029 with a CAGR of 3.5% over the forecast period.
Global Hormonal Contraceptives Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029- Increasing number of unintended pregnancies, rising initiatives for awareness about family planning and growing availability of novel contraceptives methods are major factors anticipated to drive the growth of the Global Hormonal Contraceptives Market within the Forecast Period.
The birth controls that act on endocrine systems are called hormonal contraception. In 1960 the first original hormonal method that is the combined oral contraceptive pill was first marketed. There are two main types of hormonal contraceptives that is combined method, and which contain both an estrogen and a progestin, hormones and which work by suppressing ovulation and thickening and second type is progestogen-only methods in which frequency of ovulation is reduced reduce the frequency of ovulation these hormones also thicken cervical mucus so to prevent sperm from reaching the egg. The safe and effective emergency contraception are recommended by gynecologist and healthcare professionals.
The Covid-19 pandemic has had a significant impact on the global hormonal contraceptives market, including supply chain disruptions, reduced demand, changes in healthcare delivery, and government policy changes. These factors have led to shortages of some hormonal contraceptives in some regions, reduced access to contraception for some people, and a mixed impact on demand for hormonal contraceptives overall.
The global hormonal contraceptives market is segmented into product type, end users and region & country level. On the basis of product type, the global hormonal contraceptives market is segmented into intrauterine device (IUD), injectable birth control, pill, vaginal ring, implant, and patch. On the basis of end users, the market is segmented into homecare, gynecology centers and clinics.
The regions covered in global hormonal contraceptives market report are North America, Europe, Asia-Pacific, Latin America, and Rest of the World. Based on country level, the market of global hormonal contraceptives market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, Southeast Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
Some of the key players for global hormonal contraceptives market are -
One of the major factors driving the growth of the global hormonal contraceptives market is the increasing number of unintended pregnancies. For instance; early half of all pregnancies, totaling 121 million each year worldwide, are unintended, according to a new report published on 30th March 2022 by the UN’s sexual and reproductive health agency. Thus, the use of effective methods of contraception for avoiding unwanted pregnancies is further driving to market growth for the forecast period. In addition, the rising initiatives for creating awareness about family planning to make people aware of the contraceptives that aid in avoiding pregnancy are also supplementing the market growth.
Moreover, growing availability of novel contraceptives methods and increasing number of approvals are further fostering the market growth. For example; as per news published on April 16th, 2021, a new oral contraceptive NEXTSTELLIS was approved by U.S Food and Drug Administration. However, side effects associated with hormonal contraceptives such as depression and mood swings may hinder the market growth. In spite of that, rising awareness and introduction of safe and effective medications of hormonal contraception may offer more opportunities for the further growth of market.
The North America is expected to dominate the global hormonal contraceptives market due to increasing number of unintended pregnancies, rising research and development and supportive government initiatives for family planning in this region. For instance; above three million unplanned pregnancies occur in U.S every year as per National Center of Biotechnology and Information. In addition, rising research and development activities and product approvals in this region are further augmenting the market growth. For example; a combination drospirenone and estetrol tablet for the prevention of pregnancy was approved by U.S Food and Drug Administration on April 19th, 2021. Moreover, supportive government initiatives for creating awareness amongst people about contraceptives further are also boosting the market growth in this region.
Asia Pacific is expected to be fastest growing region in the global hormonal contraceptives market due to initiatives by government, rising use of contraception and introduction of novel contraception devices for females in this region. For instance; nationwide campaign "Youth Dialogue- A perspective on FP 2020" to create awareness on 'Sexual and Reproductive Health and Rights for all launched by Family Planning Association of India (FPA India) in 2020. In addition, the report by FP2020, a global partnership that supports the reproductive rights of women and girls, above 139 million women and girls in India now use modern methods of contraception as per news published on January 26th, 2021.
Boots Planned to Launch First Contraceptive Pill Made Available Over the Counter
On July 12th, 2021; The contraceptive pills without prescription announced by Boots in U.K. According to the Medicines and Healthcare products Regulatory Agency (MHRA) pills can be purchased after consultation. The pills which contain 75mg desogestrel and if purchased at Boots.com, the patient will be required to fill out a form online which will be subject to clinical review and pharmacist approval.
Prasco Announced Launch the Authorized Generic of NuvaRing
On December 16th, 2019; The launch of the Authorized Generic of NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) was announced by Prasco. The product was made in partnership with Merck & Co., Inc., and it was the 9th women’s health product Prasco has brought to market. The NuvaRing is also called as Ethinyl Estradiol Vaginal Ring is a small, flexible vaginal ring used by women to prevent pregnancy.
|Historical data||2016 - 2021|
|Forecast Period||2022 - 2029|
|Market Size in 2022:||USD 16.36 Billion|
|Base year considered||2021|
|Forecast Period CAGR %:||3.5%|
|Market Size Expected in 2029:||USD 28.81 Billion|
|Tables, Charts & Figures:||175|
|Key Players/Companies||Cipla Limited., Agile Therapeutics, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell Ltd., Mayer Laboratories, Merck & Co., Inc., Church & Dwight, Co., Inc., Afaxys, Inc., Allergan Plc, Apothecus Pharmaceutical Corporation., Novartis AG, Sun Pharmaceutical Industries Ltd., and others|
|Segments Covered||By Product Type, By End Users|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|